Adeno-associated virus (AAV) forms the basis of one of the most promising and versatile vector systems for therapeutic human gene transfer. The genetic simplicity and low immunogenicity, paired with high plasticity and amenability to engineer and repurpose the viral capsid and genome, make it a popular choice for gene therapy.
In this webinar, our distinguished guests, Dr. Dirk Grimm and Dr. David Schaffer will
Discuss the concept of using directed evolution to engineer highly optimized variants of AAV for a broad range of cell and tissue targets.
Introduce key technologies for targeted modification and directed evolution of critical AAV components
Address vector delivery barriers using directed evolution approaches
Attendees will discover novel approaches to: